Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ · IEX Real-Time Price · USD
0.370
+0.021 (5.99%)
Jul 22, 2024, 11:26 AM EDT - Market open
Mainz Biomed B.V. Employees
As of December 31, 2023, Mainz Biomed B.V. had 71 total employees, including 65 full-time and 6 part-time employees. The number of employees increased by 7 or 10.94% compared to the previous year.
Employees
71
Change (1Y)
7
Growth (1Y)
10.94%
Revenue / Employee
$12,612
Profits / Employee
-$370,362
Market Cap
7.86M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71 | 7 | 10.94% |
Dec 31, 2022 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
XWELL | 337 |
Vivos Therapeutics | 123 |
iCoreConnect | 70 |
NeuroMetrix | 26 |
Kineta | 13 |
Innovative Eyewear | 11 |
Shuttle Pharmaceuticals Holdings | 8 |
Virpax Pharmaceuticals | 7 |
MYNZ News
- 13 days ago - Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test - GlobeNewsWire
- 20 days ago - Mainz Biomed Provides Half Year 2024 Corporate Update - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Reports Results of 2024 Annual General Meeting - GlobeNewsWire
- 7 weeks ago - Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial - GlobeNewsWire
- 2 months ago - Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. - GlobeNewsWire
- 3 months ago - Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic - GlobeNewsWire